

Increased BDNF levels after a trauma A pilot study on clinical and non-clinical samples, exposed or non-exposed to an earthquake

Paolo Stratta¹, Roberto L. Bonanni¹, Francesca Pacitti²,
Adriano Angelucci², Nicola Origlia³, Luciano Domenici^{3,4†}, Claudia
Carmassi⁵, Liliana Dell'Osso⁵, Alessandro Rossi⁴

¹ Department of Mental Health, ASL 1, L'Aquila, Italy; ² Cellular Pathology Laboratory, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Italy; ³ Neuroscience Institute, CNR, Pisa, Italy; ⁴ Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Italy; ⁵ Department of Clinical and Experimental Medicine, University of Pisa, Italy

SUMMARY

Background

Brain-Derived Neurotrophic Factor (BDNF) modulates synaptic modifications that can constitute part of brain adaptive processes in the aftermath of trauma exposure. Thus, BDNF increase could be determined either in psychiatric patients or healthy subjects who, despite exposed to stressful events, did not develop stress-related symptoms.

Methods

BDNF plasma levels were evaluated in a clinical and a non-clinical populations exposed to the 2009 L'Aquila earthquake and in a comparable population not exposed to such event or other trauma.

Results

Statistically significant differences emerged according to diagnosis (clinical samples vs. controls), while a trend toward significance was found according to exposure (exposed vs. not-exposed subjects). The exposed clinical sample showed statistically significant higher BDNF levels than the not-exposed one.

Conclusions

Lack of statistical difference between exposed and not exposed subjects suggests that no BDNF modification intervened after the stressful event. Exposed samples however showed the highest BDNF levels with a trend toward significance. A ceiling effect that impede the possibility of exceeding a possible maximum level in the control sample can be hypothesized. Clinical sample shows instead room for stress related BDNF increase. If so, such a BDNF increase could have a neuroprotective adaptive role after stress.

Key words: Brain-Derived Neurotrophic Factor (BDNF), stress event, ceiling effect, stress adaptation, earthquake

Received: December 5, 2019

Accepted: January 13, 2020

Correspondence

Paolo Stratta

Department of Mental Health, ASL 1, via Capo

Croce 1, 67100 L'Aquila, Italy

E-mail: psystr@tin.it

Conflict of interest

The Authors declare no conflict of interest

How to cite this article: Stratta P, Bonanni RL, Pacitti F, et al. Increased BDNF levels after a trauma. A pilot study on clinical and non-clinical samples, exposed or non-exposed to an earthquake. *Journal of Psychopathology* 2020;26:36-40. <https://doi.org/10.36148/2284-0249-363>

© Copyright by Pacini Editore Srl



OPEN ACCESS

This is an open access Journal distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Introduction

Brain-Derived Neurotrophic Factor (BDNF) is one of the most important neurotrophin involved in cerebral synaptic plasticity and cognitive functions regulation. It is highly sensitive to environmental factors and its increase enhances neurogenesis, neurite sprouting, electrophysiological activity with beneficial effects on cognitive functions such as learning and memory¹⁻³. Alterations in the BDNF expression and functioning has been widely linked with stress both in animal and clinical studies suggesting a possible resilience correlate⁴⁻¹³.

Synaptic modifications can constitute an adaptive process to stress events and BDNF is a relevant modulator of such modifications¹⁴. In the aftermath of stressful events exposure, a relevant information processing is needed in order to identify opportunities and possibilities to overcome the encountered difficulties. Serum BDNF levels have been reported to be involved in decision-making processes¹⁵.

If the process is successful, the rapid BDNF capacity of performing cerebral modifications could avoid unwanted stress consequences and pathologies^{16,17}. On the other hand, if no such neurotrophin and synaptic plasticity modifications append, pathological stress consequences could result¹⁸.

In this study, we aimed to study BDNF changes in subjects who did not show psychiatric symptoms or worsening of symptoms despite having experienced a relevant stress event such as an earthquake.

We hypothesized that if no stress-related symptom or relapse/worsening of ongoing psychopathology appeared in subjects who suffered relevant stress, BDNF variation could be due to stress exposure. Thus, we enrolled a sample of subjects exposed to the same stress event, i.e. a clinical and non-clinical populations exposed to a natural catastrophe (i.e. the 2009 L'Aquila earthquake), and compared it to a similar population not exposed to such trauma. Because natural disasters are random events that expose unselected populations to the same trauma, they offer the opportunity to explore the effects 'triggered' by a unique trauma, disentangling confounding issues of pre-existing risk for exposure to traumatic events.

Methods

Study participants

In the framework of a study on clinical and neurobiological factors related to post-traumatic stress spectrum symptomatology in the aftermath of an earthquake exposure¹², we considered a sample of healthy control subjects and depressed/anxious patients exposed to such trauma compared to a sample of healthy control subjects and depressed/anxious patients not exposed to this event or to other relevant trauma.

The total sample included: 1) fifteen healthy control subjects with no current or lifetime DSM-IV-TR disorder or use of psychotropic medication exposed to the L'Aquila 2009 earthquake (10 women and 5 men; mean age \pm SD: 46.3 \pm 10.6 years); 2) a consecutive sample of 11 outpatients (5 women and 6 men; mean age \pm SD - 42.2 \pm 10.2 years), 8 with major depression (MDD) and 3 with panic disorder (PD). These subjects were diagnosed before the earthquake and did not show worsening or relapse of the symptoms after the event. The healthy subjects were recruited from among

those accompanying the outpatients. The recruitment was performed about two years after the traumatic event (July-December 2011) at the National Mental Health Care Service facilities in L'Aquila; 3) a consecutive sample of 10 outpatients (5 women and 5 men; mean age \pm SD 52.3 \pm 12.3 years) with a diagnosis of MDD or PD were recruited at the Clinic of Psychiatry of the Department of Clinical and Experimental Medicine of the University of Pisa (Italy); 4) thirty-seven healthy control subjects were enrolled from Pisa (23 women and 14 men; mean age \pm SD 33.1 \pm 7.4 years) by the same recruitment method used in L'Aquila. These two latter samples were not exposed to the L'Aquila 2009 earthquake or to other relevant trauma in their lifetime.

At the time of BDNF evaluation all patients were treated with low doses of benzodiazepines and / or antidepressants, as the Ethical Committee did not allow any drug free period. No patients were treated with antipsychotics or mood stabilizers.

The Ethics Committees of the Azienda Sanitaria Locale of L'Aquila and of the Azienda Ospedaliero - Universitaria of Pisa approved all recruitment and assessment procedures. All subjects included provided written informed consent, after receiving a complete description of the study and having the opportunity to ask questions.

Procedures

All subjects were assessed by means of the: Structured Clinical Interview for DSM-IV Axis-I disorders Patient Version (SCID-I/P)¹⁹ for psychiatric diagnoses; Clinical Global Impression (CGI), for the severity of illness.

Venous blood samples were taken in the morning (between 8:00 and 9:00 am), to avoid diurnal variations of BDNF levels²⁰. Blood samples were processed using enzyme-linked immunosorbent assay (ELISA) protocol on plasma to determine BDNF values that are expressed as pg/ml.

Statistical analyses

The descriptive statistics on the BDNF levels showed high skewness (1.33) and kurtosis (2.75). In order to control the gaussian distribution, BDNF values were log transformed reaching satisfactorily distribution indexes (skewness - 0.31 and kurtosis - 0.24). One-way analysis of variance (ANOVA) and two-way analysis of covariance (ANCOVA) were utilized. Main effects were further analyzed with post hoc planned t-test analysis. Chi square and Pearson's r correlation were also used. All analyses yielding a p-value less than .05 were considered significant.

Results

Among the four sub-samples, statistically significant age differences emerged (1-way ANOVA $F = 14.9$, d.f.

TABLE I. Comparison of BDNF plasmatic levels (pg/ml, mean \pm SD) and age between depressed/anxiety (dep/anx) patients and healthy subjects, exposed or not exposed to the earthquake.

Subjects	Plasma BDNF	Age
Dep/anx exposed (n = 11)	3650.6 \pm 1648.2	42.2 \pm 10.2
Dep/anx not exposed (n = 10)	2495.0 \pm 1335.9	52.3 \pm 12.3
Controls exposed (n = 15)	6004.8 \pm 4100.2	46.3 \pm 10.6
Controls not exposed (n = 37)	5526.2 \pm 2659.4	33.1 \pm 7.4

Two-way ANCOVA for plasmatic BDNF, after natural logarithm transformation, with exposition and diagnosis as factors and age as covariate. Exposure factor $F = 2.7$; $p < 0.10$. Diagnosis factor $F = 14.3$; $p < 0.0005$. Exposure by diagnosis interaction $F = 1.6$; $p = 0.20$.

3, $p < 0.0005$), but not in gender distribution ($X^2 = 5.7$, d.f. 3, NS) or in the correlation with BDNF. No significant difference in CGI severity of illness scores between exposed and not exposed clinical samples (L'Aquila vs Pisa) was found.

BDNF plasma levels in the four sub-samples are reported in Table I. Two-way ANCOVA was used considering diagnosis, i.e. clinical sample vs controls, and exposure, i.e. earthquake exposed vs not exposed subjects, as factors; age was considered as covariate. Statistically significant difference was observed according to diagnosis ($F = 14.3$; $p < 0.0005$), but not to exposure ($F = 2.7$; $p < 0.10$), or exposure by diagnosis interaction ($F = 1.6$; NS). Post-hoc planned t-tests showed statistically significant difference between exposed and not-exposed clinical samples ($t = 2.1$, d.f. 19, $p < 0.05$).

Discussion

The lack of global statistically significant difference between earthquake exposed and not-exposed subjects would corroborate the null hypothesis that no BDNF modification intervened after the stressful event.

Some considerations however have to be made: although the difference did not reach statistical significance, exposed subjects showed the absolute highest BDNF levels, and a trend toward significance emerged with respect to not-exposed subjects ($p = 0.09$). Further, a statistically significant difference emerged in BDNF levels between the two clinical samples with exposed patients showing significantly higher levels.

The possibility of a ceiling effect cannot be excluded, in particular among healthy control subjects where it could not be possible to exceed a certain level. However, if a ceiling effect could explain findings in healthy control subjects, this could not be the case of clinical samples where a significant difference between exposed and not-exposed patients was found with almost twice as much of the neurotrophin levels in the former. Although BDNF decrease in subjects with affective disorders as well as panic disorder is a well reported finding^{21–27}, the

possibility for a stress related increase seems to be possible. As BDNF peripheral levels may parallel changes occurring in the brain, the trend of plasma BDNF increase in L'Aquila clinical and healthy control samples, with respect to not-exposed subjects, could be interpreted as a residual 'signal', two years after the trauma, related to a neuroprotective reaction to the stress.

Our results are in line with several studies from both animal and human models eventually.

Increase in BDNF expression has been observed after stress in rats hypothesized as part of a coping compensatory response to stressful stimuli^{28,29}.

In humans, subjects with trauma but not showing Post Traumatic Stress Disorder (PTSD) symptoms evidenced higher BDNF serum levels compared to patients affected by PTSD³⁰. Elevated serum BDNF levels were found in imprisoned women, likely suffering from prison-related stress without PTSD³¹. Peripheral levels elevation has been observed in worker exposed to occupational stress³². BDNF increased levels have been interpreted as further evidence of BDNF involvement in stress response, as contribution to neuron protection under stress reducing behavioral sequelae of PTSD³³.

Some important limitations should be taken into account while interpreting these results. First of all, the sample size that, despite not large, should be sufficient for a pilot study of heuristic value. Second, healthy control subjects samples required the exclusion of any kind of symptom. Third is the selection of comparison groups in a quasi-experimental design where the samples are not equated prior to manipulation of the independent variable (i.e. earthquake exposure). Fourth, the time from exposure: BDNF levels were assessed two years after the earthquake occurred and thus we cannot exclude that a putative early BDNF increase, well superior to that we observed, may have occurred in the aftermath of the event followed by a trend toward the normalization over time. Fifth, the lack of assessment of post-traumatic stress symptomatology at the time of the earthquake. Although a PTSD diagnosis has been excluded at the SCID interview, the possibility of some trauma symp-

toms could have been emerged in the aftermath of the event that could be related to BDNF modifications, cannot be excluded.

Globally, our results shed more light on the mechanisms

regulating BDNF levels in response to stress, delineating a landscape somewhat more complex than what could be expected from the somewhat inconsistent literature on PTSD alone^{5,12,13,34,35}.

References

- 1 Bekinschtein P, Cammarota M, Izquierdo I, et al. Reviews: BDNF and memory formation and storage. *Neuroscientist* 2008;14:147-56. <https://doi.org/10.1177/1073858407305850>
- 2 Quartini A, Pacitti F, Bersani G, et al. From adolescent neurogenesis to schizophrenia: opportunities, challenges and promising interventions. *Biomed Rev* 2017;28:66-73. <https://doi.org/10.14748/bmr.v28.4452>
- 3 Murray PS, Holmes P V. An overview of brain-derived neurotrophic factor and implications for excitotoxic vulnerability in the hippocampus. *Int J Pept* 2011;2011:654085. <https://doi.org/10.1155/2011/654085>
- 4 Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. *Biol Psychiatry* 2006;59:1116-27. <https://doi.org/10.1016/j.biopsych.2006.02.013>
- 5 Dell'Osso L, Carmassi C, Del Debbio A, et al. Brain-derived neurotrophic factor plasma levels in patients suffering from post-traumatic stress disorder. *Prog Neuro-Psychopharmacology Biol Psychiatry* 2009;33:899-902. <https://doi.org/10.1016/j.pnpbp.2009.04.018>
- 6 Andero R, Ressler KJ. Fear extinction and BDNF: translating animal models of PTSD to the clinic. *Genes, Brain Behav* 2012;11:503-12. <https://doi.org/10.1111/j.1601-183X.2012.00801.x>
- 7 Rakofsky JJ, Ressler KJ, Dunlop BW. BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity. *Mol Psychiatry* 2012;17:22-35. <https://doi.org/10.1038/mp.2011.121>
- 8 Rossetti MC, Tosone A, Stratta P, et al. Different roles of resilience in depressive patients with history of suicide attempt and no history of suicide attempt. *Rev Bras Psiquiatr* 2017;39:216-9. <https://doi.org/10.1590/1516-4446-2016-2045>
- 9 Karatsoreos IN, McEwen BS. Resilience and vulnerability: a neurobiological perspective. *F1000Prime Rep* 2013;5:13. <https://doi.org/10.12703/P5-13>
- 10 Machado-Vieira R, Dietrich MO, Leke R, et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. *Biol Psychiatry* 2007;61:142-4. <https://doi.org/10.1016/j.biopsych.2006.03.070>
- 11 Savitz J, van der Merwe L, Stein DJ, et al. Genotype and childhood sexual trauma moderate neurocognitive performance: a possible role for brain-derived neurotrophic factor and apolipoprotein e variants. *Biol Psychiatry* 2007;62:391-9. <https://doi.org/10.1016/j.biopsych.2006.10.017>
- 12 Stratta P, Bonanni RL, Sanità P, et al. Plasma brain-derived neurotrophic factor in earthquake survivors with full and partial post-traumatic stress disorder. *Psychiatry Clin Neurosci* 2013;67:363-4. <https://doi.org/10.1111/pcn.12064>
- 13 Stratta P, Sanità P, Bonanni RL, et al. Clinical correlates of plasma brain-derived neurotrophic factor in post-traumatic stress disorder spectrum after a natural disaster. *Psychiatry Res* 2016;244:165-70. <https://doi.org/10.1016/j.psychres.2016.07.019>
- 14 Poo M ming. Neurotrophins as synaptic modulators. *Nat Rev Neurosci* 2001;2:24-32. <https://doi.org/10.1038/35049004>
- 15 Hori H, Yoshimura R, Katsuki A, et al. Relationships between brain-derived neurotrophic factor, clinical symptoms, and decision-making in chronic schizophrenia: data from the iowa gambling task. *Front Behav Neurosci* 2014;8(DEC). <https://doi.org/10.3389/fnbeh.2014.00417>
- 16 McEwen BS. The ever-changing brain: cellular and molecular mechanisms for the effects of stressful experiences. *Dev Neurobiol* 2012;72:878-90. <https://doi.org/10.1002/dneu.20968>
- 17 McEwen BS, Eiland L, Hunter RG, et al. Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress. *Neuropharmacology* 2012;62:3-12. <https://doi.org/10.1016/j.neuropharm.2011.07.014>
- 18 Calabrese F, Molteni R, Racagni G, et al. Neuronal plasticity: a link between stress and mood disorders. *Psychoneuroendocrinology* 2009;34(Suppl 1). <https://doi.org/10.1016/j.psyneuen.2009.05.014>
- 19 First M, Spitzer R, Gibbon M, et al. Structured clinical interview for DSM-IV-TR Axis I disorders: patient edition, 2005.
- 20 Piccinni A, Marazziti D, Del Debbio A, et al. Diurnal variation of plasma brain-derived neurotrophic factor (BDNF) in humans: an analysis of sex differences. *Chronobiol Int* 2008;25:819-26. <https://doi.org/10.1080/07420520802387773>
- 21 Lee BH, Kim H, Park SH, et al. Decreased plasma BDNF level in depressive patients. *J Affect Disord* 2007;101:239-44. <https://doi.org/10.1016/j.jad.2006.11.005>
- 22 Piccinni A, Marazziti D, Catena M, et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. *J Affect Disord* 2008;105:279-83. <https://doi.org/10.1016/j.jad.2007.05.005>
- 23 Pandey GN, Dwivedi Y, Rizavi HS, et al. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. *Prog Neuro-Psychopharmacology Biol Psychiatry* 2010;34:645-51. <https://doi.org/10.1016/j.pnpbp.2010.03.003>
- 24 Sözeri-Varma G, Enli Y, Toker-Uğurlu T, et al. Decreased serum BDNF levels in major depressive patients. *Neurol Psychiatry Brain Res* 2011;17:84-8. <https://doi.org/10.1016/j.npbr.2011.09.001>
- 25 Kobayashi K, Shimizu E, Hashimoto K, et al. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. *Prog Neuro-Psychopharmacology Biol Psychiatry* 2005;29:658-63. <https://doi.org/10.1016/j.pnpbp.2005.04.010>
- 26 Ströhle A, Stoy M, Graetz B, et al. Acute exercise ameliorates reduced brain-derived neurotrophic factor in patients with panic disorder. *Psychoneuroendocrinology* 2010;35:364-8. <https://doi.org/10.1016/j.psyneuen.2009.07.013>
- 27 Tirassa P, Iannitelli A, Sornelli F, et al. Daily serum and salivary BDNF levels correlate with morning-evening personality type in women and are affected by light therapy. *Riv Psichiatr* 2012;47:527-34. <https://doi.org/10.1708/1183.13096>
- 28 Marmigère F, Givalois L, Rage F, et al. Rapid induction of BDNF expression in the hippocampus during immobilization stress challenge in adult rats. *Hippocampus* 2003;13:646-55. <https://doi.org/10.1002/hipo.10109>
- 29 Tsukinoki K, Saruta J. Role of stress-related brain-derived neurotrophic factor (BDNF) in the rat submandibular gland. *Acta Histochem Cytochem* 2012;45:261-7. <https://doi.org/10.12677/ahc.12017>
- 30 Angelucci F, Ricci V, Gelfo F, et al. BDNF serum levels in subjects developing or not post-traumatic stress disorder after trauma exposure. *Brain Cogn* 2014;84:118-22. <https://doi.org/10.1016/j.bandc.2013.11.012>
- 31 Dotta-Panichi RM, Bins HD, Tramontina

- JF, et al. Serum concentrations of brain-derived neurotrophic factor and mental disorders in imprisoned women. *Rev Bras Psiquiatr* 2015;37:113-20. <https://doi.org/10.1590/1516-4446-2014-1421>
- ³² Buselli R, Veltri A, Baldanzi S, et al. Plasma Brain-Derived Neurotrophic Factor (BDNF) and serum cortisol levels in a sample of workers exposed to occupational stress and suffering from adjustment disorders. *Brain Behav* 2019;9(7). <https://doi.org/10.1002/brb3.1298>
- ³³ Kaplan GB, Vasterling JJ, Vedak PC. Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. *Behav Pharmacol* 2010;21:427-37. <https://doi.org/10.1097/FBP.0b013e32833d8bc9>
- ³⁴ Hauck S, Kapczinski F, Roesler R, et al. Serum brain-derived neurotrophic factor in patients with trauma psychopathology. *Prog Neuro-Psychopharmacology Biol Psychiatry* 2010;34:459-62. <https://doi.org/10.1016/j.pnpbp.2010.01.010>
- ³⁵ Bonne O, Gill JM, Luckenbaugh DA, et al. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with post-traumatic stress disorder before and after treatment with paroxetine. *J Clin Psychiatry* 2011;72:1124-8. <https://doi.org/10.4088/JCP.09m05106blu>